4
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Beta Adrenergic Blockers and Cyclic AMP Dependent Agents in Patients with Heart Failure

Pages 239-247 | Published online: 28 Sep 2008

References

  • Dies F, Krell M J, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 1986; 74: 38, SupplII
  • Goldberg A D, Goldstein S, Nicklas J. Multicenter trial of imazoden in patients with chronic congestive heart failure. Circulation 1990; 82: 673, Suppl III
  • Vietsky B F, Jessup M, Konstan M A, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation 1990; 82: 774–780
  • Packer M, et al. The Promise Trial. presented at the 40th Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March, 3–71991, Personal communication
  • Yusuf S, Teo K. Inotropic agents increase mortality in patients with congestive heart failure. Circulation 1990; 82: 673, Suppl III
  • Pouleur H, Rousseau M F, Van Eyll C A, et al. Progression of left ventricular dysfunction: remodeling or depressed contractility?. Circulation 1990; 82: 123, Suppl III
  • The SOLVD Investigators. Studies of Left Ventricular Dysfunction (SOLVD) -rationale, design methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol 1990; 36: 315–322
  • The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–1435
  • Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406–412
  • Nicklas J M, Mickelson J K, Das S K, Morady F, Schork M A, Pitt B. Prospective, randomized double blind, placebo controlled trial of low-dose amiodarone in patients with severe heart failure and frequent ventricular ectopy. Circulation 1988; 78: 27, Suppl II
  • Pfisterer M, Burkart F, Kiowski W. Protective effect of amiodarone after myocardial infarction in patients with complex arrhythmias and preserved but not impaired LV function. Circulation 1990; 82: 197, Suppl II
  • Cohn J N, Levine T B, Olivari M T, Garberg V, Lura D, Francis G S, Simon A B, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819–823
  • Muller J E, Stone E, Turi Z G, et al, the MfLIS Study Group. Orcadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315
  • Furberg C D, Hawkins C M, Lichtein E, for the Beta Blocker Heart Attack Trial Study Group. Effect of propranolol in post infarction patients with mechanical or electrical complications. Circulation 1984; 69: 761–765
  • Chadda K, Goldstein S, Byington R, Cub J D. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986; 73: 503–510
  • Heilbrann S M, Shah P, Bristow M R, Valantine H A, Ginsberg R, Fowler M B. Increased BO-receptor density and improved hemodynamic response to catecholamine stimulation during long term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 1989; 79: 483–90
  • Inoue H, Zipes D P. Results of sympathetic denervation in the canine heart: hypersensitivity that may be arrhythmogenic. Circulation 1987; 75: 877–887
  • Yates J C, Beamish R E, Shalla N S. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. Am Heart J 1981; 102: 210–221
  • Beamish R E, Dillon K S, Singhal P K, Shalla N S. Protective effect of sulfinpyrazone against catecholamine metabolite adrenodrone-induced arrhythmias. Am Heart J 1981; 102: 149–157
  • Kukreja R C, Kontos H A, Eaton L R, Hiss M L. Captopril and enalaprilat do not scavenge the superoxide ancion. Am J Cardiol 1990; 65: 241–271
  • Lynch J J, Kitzen J M, Hoff P T, Lucchesi B B. Reduction in digitalis associated postinfarction mortality with nadolol in conscious dogs. Am Heart J 1988; 115: 67–76
  • Cubeddu L X, Fuenmayor N, Varin F, Willagra V G, Colindres R E, Powell J R. Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. J Cardiovasc Pharmacol 1987; 10: S81–S84, (Suppl II)
  • Van de Water A, Janeens W, Van Nueten J, Xhonneux R, De Cree J, Verhaegen H, Reneman R S, Janssen P AJ. The pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent and selective beta-adrenergic antagonist. J Cardiovasc Pharm. 1988; 11: 552–563
  • The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336: 1–6
  • The Xamoterol in Severe Heart Failure Study Group. Xamoterol in Severe Heart Failure. The Lancet 1990; 336: 1–6
  • Teo K, Held P, Collins B, Yusuf S. Effect of intravenous magnesium on mortality in myocardial infarction. Circulation 1990; 82: 393, (Suppl III)
  • Von Euler V S, Lishajiko F. Effects of Mg and Ca on nor-adrenaline release and uptake in adrenergic nerve gradules in different media. Acta Physiol Scand 1983; 89: 415

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.